How Accurate Is Cologuard? Cancer Detection, False Alarms, and the Real Trade-Off
In the largest trial of Cologuard, the at-home stool DNA test caught 92.3% of colorectal cancers in nearly 10,000 average-risk adults, compared with 73.8% for the standard fecal immunochemical test (FIT).
That headline number is what most people see in marketing material. The honest answer to "how accurate is Cologuard?" depends entirely on what you're trying to detect. The test is genuinely good at catching cancer, weaker at catching the precancerous polyps you'd actually want to remove before they turn malignant, and prone to flagging people who turn out to have nothing wrong on follow-up colonoscopy. Knowing the specific trade-offs helps you decide whether it's the right screening tool for you.
How Cologuard Performed in the Pivotal Trial
Cologuard was approved on the strength of a 2014 study called DeeP-C. The trial enrolled 9,989 average-risk adults who all underwent colonoscopy as the gold-standard comparison.
Key results across the full cohort:
- Colorectal cancer sensitivity: 92.3% (Cologuard caught 60 of 65 cancers found at colonoscopy)
- Advanced precancerous lesion sensitivity: 42.4% (it caught fewer than half of the large adenomas and serrated polyps that haven't yet turned cancerous)
- Specificity in people with no advanced findings: 86.6% (about 13% of healthy people got a positive result anyway)
- Specificity in people with completely negative colonoscopy: 89.8%
A next-generation version of Cologuard underwent a similar trial called BLUE-C, published in 2024. With 20,176 participants, the updated test posted broadly similar numbers: 93.9% sensitivity for cancer, 43.4% sensitivity for advanced precancerous lesions, and improved specificity around 90.6% for advanced neoplasia. The cancer-catching performance is essentially unchanged; the improvement is mostly on the specificity side, meaning fewer healthy people get falsely flagged.
Where Cologuard Beats FIT, and Where It Doesn't
The most useful comparison isn't Cologuard vs colonoscopy (colonoscopy will always be more accurate because it lets a doctor see and remove polyps directly). The relevant comparison is Cologuard vs FIT, the cheaper annual stool test that's also recommended for average-risk screening.
| Test outcome | Cologuard | FIT | Source |
|---|---|---|---|
| Catches colorectal cancer | 92 to 94% | 67 to 74% | |
| Catches advanced precancerous lesions | 42 to 46% | 23 to 27% | |
| Specificity (no advanced findings) | 87 to 91% | 95 to 96% | |
| Recommended interval | Every 3 years | Every year | |
| Out-of-pocket cost | $599 | $89 | catalog |
Cologuard finds more cancers and more advanced polyps in a single test. But FIT, taken every year, accumulates its own detection power, and it produces about half as many false positives. The 2018 American Cancer Society guideline endorses both tests as legitimate options for average-risk adults aged 45 to 75, alongside colonoscopy every 10 years.
One genuinely impressive Cologuard finding: it catches sessile serrated polyps (a flat, easy-to-miss precancerous type that often hides in the right side of the colon) at much higher rates than FIT, 42.4% versus 5.1% in the pivotal trial. If your family history skews toward right-sided cancers or these specific polyp types, that gap matters.
The False-Positive Problem
The flip side of catching more cancers is flagging more healthy people. In the pivotal trial, 13.4% of people with no advanced findings on colonoscopy still got a positive Cologuard result. Because cancer prevalence in the average-risk screening population is low (0.7% in the same trial), most positive Cologuard results in healthy adults won't trace back to cancer or even an advanced precancerous lesion.
Why does this matter? Every positive Cologuard requires a follow-up colonoscopy to figure out what's going on. So if you screen with Cologuard, the question isn't really "do I get a colonoscopy?" but "do I get a colonoscopy now (planned), or do I get one later (after a possibly false-positive stool test)?"
For the right person, that's an acceptable trade. For someone who'd rather just get one definitive test every 10 years, FIT or direct colonoscopy may fit better.
How It Performs Outside Clinical Trials
Trial numbers describe what the test can do under controlled conditions. Real-world data tells you what actually happens.
A study of more than 1.4 million insured patients shipped Cologuard in 2018 found that 66.8% of people actually completed and returned the test within a year. Adherence rose with age (74.7% in those 76 and older versus 60.8% in those 50 to 64) and was higher among Medicare patients than commercially insured ones. By stool-test standards, that completion rate is high and reflects the company's outreach and reminder system.
For specific populations with limited access to colonoscopy, the value proposition is even stronger. In a study of 661 Alaska Native adults, who have among the world's highest colorectal cancer rates, Cologuard detected 100% of cancers (10 of 10) and 49% of screening-relevant lesions, compared with 80% and 28% respectively for FIT. A cost-effectiveness analysis in the same population found Cologuard either dominated or was cost-effective compared with both FIT and colonoscopy across most adherence scenarios.
In broader populations, the cost-effectiveness picture is less favorable. A 2016 modeling analysis assumed equal adherence across screening strategies and found that annual FIT and 10-year colonoscopy were both more effective and less costly than triennial Cologuard. A 2020 microsimulation put annual Cologuard at an incremental cost of about $215,000 per quality-adjusted life-year gained, well above the typical $100,000 willingness-to-pay threshold. Cologuard becomes cost-effective mainly when it pulls in people who would otherwise skip screening entirely.
What the Numbers Mean If You're Choosing a Test
The honest framing for an average-risk adult at age 45 or older is this:
- You want maximum cancer detection in a single test, at home, with no prep. Cologuard catches roughly 92 to 94% of cancers in one go, the highest of any noninvasive option. It's a strong choice if you'd otherwise skip screening entirely.
- You want maximum precancerous lesion detection. Colonoscopy is still better. It finds and removes polyps in one visit. Cologuard catches fewer than half.
- You want the lowest false-positive rate. Annual FIT wins on specificity, with about 4 to 5% false positives versus 7 to 13% for Cologuard.
- You care most about minimizing follow-up colonoscopies. FIT or direct colonoscopy at the recommended interval beats Cologuard.
If Cologuard fits your situation, you can order Cologuard ($599) at home, no prep, no time off work, no referral needed. Results typically come back within two weeks. A positive result triggers a follow-up colonoscopy; a negative result means you're cleared for three years.
The bigger picture: any of the recommended screening options will dramatically reduce your colorectal cancer risk if you actually use it. The 2024 next-gen Cologuard data and the 2018 ACS guideline agree on the same fundamental point. The best screening test is the one you'll actually do.
No referral needed. Results reviewed by a physician.